Loading stock data…
Aquestive Therapeutics, Inc. (AQST)
$4.39-0.07 (-1.68%)
Market ClosedLast close Jun 26
Aquestive Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aquestive Therapeutics, Inc. in the Healthcare sector is trading at $4.39 with a market capitalization of $592M. Wall Street consensus targets $8.89 (9 analysts), implying a +102.5% move over the next 12 months. The stock is currently 42% below its 52-week high of $7.55, remaining 10.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +102.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.45M↑ | $13.02M↑ | $12.81M↑ | $10.00M↑ | $8.72M |
| Gross Profit | $10.98M↑ | $7.18M↓ | $8.30M↑ | $5.44M↑ | $5.07M |
| Operating Income | -$4.20M↑ | -$28.84M↓ | -$11.48M↓ | -$11.37M↑ | -$19.36M |
| Net Income | -$8.06M↑ | -$31.86M↓ | -$15.45M↓ | -$13.55M↑ | -$22.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$592.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
202.36%
Volume
Today's trading volume
7.38M
Recent News
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Does US manufacturing give drugmakers a speed edge?
Aquestive’s fast response to an FDA rejection reveals why some drugmakers are betting on domestic operations despite pricing pressures and overseas supply dependencies.
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) just kicked off its latest quarterly results with some...
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Aquestive Therapeutics Inc (AQST) reports a 66% revenue increase and outlines strategic milestones, despite challenges in product launch timelines.
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss. On the company’s first-